NCT05835570Recruiting
Integrin αvβ6-targeted PET in Malignant Tumors
A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography (PET) for Malignant Tumors
Source: ClinicalTrials.gov · Last updated 30 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 18 Apr 2023
- Start date
- 1 Jan 2023
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Zhongnan Hospital
- Diseases
- Lung cancer, Metastatic breast cancer
- NCT number
- NCT05835570
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2023 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another clinical trial within 30 days prior to PET/CT scan;
Other illness
- Known allergy to injection or its excipients;
- Claustrophobia or other psychiatric disorders;
- History of other malignant tumors;
- Other conditions deemed unsuitable for inclusion by investigator.
Other
- Severe liver or renal dysfunction;
- Pregnant or breastfeeding women;
- Refusal to participate or request for withdrawing from the clinical study;
Who the study is looking for
- Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
- Age ≥18 years, regardless of gender;
- No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
- Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;
- Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongnan Hospital of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.